{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:21:07Z","timestamp":1783689667927,"version":"3.55.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115254","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T07:30:33Z","timestamp":1691047833000},"page":"115254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients \u2013 Lessons learned from the COVID-19 pandemic"],"prefix":"10.1016","volume":"165","author":[{"given":"Jakub","family":"Wro\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Ciechomska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kuca-Warnawin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"American college of rheumatology\/arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2023.115254_bib6","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib8","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.biopha.2023.115254_bib10","unstructured":"Global Methotrexate Industry Research Report 2023 Competitive Landscape Market \u2013 Industry Reports. Available from: \u3008https:\/\/www.industryresearch.biz\/global-methotrexate-industry-research-report-2023-competitive-landscape-market-22358507#utm_source=MWYD\u3009 [accessed March 1, 2023]."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J. Rheumatol."},{"issue":"39","key":"10.1016\/j.biopha.2023.115254_bib13","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis","volume":"36","author":"van Aalst","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2023.115254_bib15","unstructured":"Adult Immunization Schedule \u2013 Healthcare Providers | CDC. Available from: \u3008https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult.html\u3009 [accessed March 9, 2023]."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00124743-199604000-00001","article-title":"Pneumococcal vaccine in rheumatoid arthritis","volume":"2","author":"O\u2019Dell","year":"1996","journal-title":"J. Clin. Rheuma"},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib17","article-title":"Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus","volume":"17","author":"Migita","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s10067-011-1856-5","article-title":"Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs","volume":"30","author":"Kapetanovic","year":"2011","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.biopha.2023.115254_bib20","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202658","article-title":"Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy","volume":"72","author":"Mori","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.130945","article-title":"Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial","volume":"41","author":"Kivitz","year":"2014","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib22","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.vaccine.2016.12.068","article-title":"Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine","volume":"35","author":"Kapetanovic","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0019-6","article-title":"Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sj\u00f6gren\u2019s syndrome without disease modifying treatment","volume":"2","author":"Nived","year":"2018","journal-title":"BMC Rheumatol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib27","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheumatol.."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib28","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/ar4127","article-title":"Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib29","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheumatol."},{"issue":"52","key":"10.1016\/j.biopha.2023.115254_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002184","article-title":"Opsonic and antibody responses to pneumococcal polysaccharide in rheumatoid arthritis patients receiving golimumab plus methotrexate","volume":"94","author":"Migita","year":"2015","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib32","article-title":"Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients","volume":"17","author":"Migita","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib33","first-page":"1356","article-title":"Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept","volume":"31","author":"Mease","year":"2004","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib34","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/ard.2010.144451","article-title":"Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate","volume":"70","author":"Coulson","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03009742.2020.1732459","article-title":"Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status","volume":"49","author":"Rasmussen","year":"2020","journal-title":"Scand. J. Rheumatol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001041","volume":"5","author":"Furer","year":"2019","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/annrheumdis-2021-221461","article-title":"Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19","volume":"81","author":"Bower","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib38","first-page":"2555","article-title":"Specific antibody response after influenza immunization in systemic lupus erythematosus","volume":"29","author":"Abu-Shakra","year":"2002","journal-title":"J. Rheumaatol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","article-title":"Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients","volume":"46","author":"Kapetanovic","year":"2007","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.semarthrit.2008.12.002","article-title":"The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"39","author":"Elkayam","year":"2010","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"Van Assen","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/ar3542","article-title":"Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor","volume":"13","author":"Kobie","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib44","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/ard.2011.152983","article-title":"Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice","volume":"70","author":"Ribeiro","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib45","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","article-title":"Protective effect of A\/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study","volume":"51","author":"Adler","year":"2012","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib46","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/art.30325","article-title":"Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study","volume":"63","author":"Gabay","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.biopha.2023.115254_bib47","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","article-title":"TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients","volume":"51","author":"Fran\u00e7a","year":"2012","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib48","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","article-title":"Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis","volume":"71","author":"Mori","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib49","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/acr.21838","article-title":"Abatacept and reduced immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis","volume":"65","author":"Ribeiro","year":"2013","journal-title":"Arthritis Care Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/ar4427","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.130945","article-title":"Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial","volume":"41","author":"Kivitz","year":"2014","journal-title":"J. Rheumaatol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10067-013-2483-0","article-title":"Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis","volume":"33","author":"Kogure","year":"2014","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/03009742.2013.788733","article-title":"Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort","volume":"42","author":"Kobashigawa","year":"2013","journal-title":"Scand. J. Rheumatol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib54","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1093\/rheumatology\/keaa078","article-title":"Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs","volume":"59","author":"Nakafero","year":"2020","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib55","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/1756-185X.13322","article-title":"Clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis","volume":"21","author":"Chen","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2023.115254_bib56","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/rheumatology\/kez045","article-title":"Safety and immunogenicity of tetanus\/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study","volume":"58","author":"B\u00fchler","year":"2019","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217221","article-title":"Reduced IgG titers against pertussis in rheumatoid arthritis: evidence for a citrulline-biased immune response and medication effects","volume":"14","author":"Holmes","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib58","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA","volume":"74","author":"Bingham","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib59","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.biopha.2023.115254_bib60","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1080\/21645515.2018.1460292","article-title":"Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study","volume":"14","author":"Kovac","year":"2018","journal-title":"Hum. Vaccine Immunother."},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib61","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk factors for herpes zoster: a systematic review and meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib62","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3899\/jrheum.160685","article-title":"Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases","volume":"44","author":"Yun","year":"2017","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115254_bib63","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115254_bib64","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.7326\/M20-6928","article-title":"The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: a randomized controlled trial","volume":"174","author":"Curtis","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"22","key":"10.1016\/j.biopha.2023.115254_bib65","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"New Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib66","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/cid\/cix484","article-title":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial","volume":"65","author":"Eberhardson","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib67","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3899\/jrheum.170936","article-title":"Safety, and humoral and cell-mediated immune responses to herpes zoster vaccine in patients with rheumatoid arthritis","volume":"45","author":"Koh","year":"2018","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib68","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.24010","article-title":"Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post hoc analysis of data from a phase IIIb\/IV randomized study","volume":"72","author":"Calabrese","year":"2020","journal-title":"Arthritis Care Res."},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib70","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib71","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center\u2019s experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115254_bib72","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib73","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/acr.20045","article-title":"Yellow fever revaccination during infliximab therapy","volume":"62","author":"Scheinberg","year":"2010","journal-title":"Arthritis Care Res."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib74","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.38960","article-title":"Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever","volume":"67","author":"Oliveira","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa126","article-title":"Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1","volume":"27","author":"Buhler","year":"2020","journal-title":"J. Travel Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/S0037-86822009000100006","article-title":"Vacina\u00e7\u00e3o contra febre amarela em pacientes com diagn\u00f3sticos de doen\u00e7as reum\u00e1ticas, em uso de imunossupressores","volume":"42","author":"Mota","year":"2009","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.biopha.2023.115254_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215403","article-title":"Inadvertent yellow fever vaccination of a patient with Crohn\u2019s disease treated with infliximab and methotrexate: Table 1","author":"Ekenberg","year":"2016","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib78","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax082","article-title":"Safety of live vaccines on immunosuppressive or immunomodulatory therapy\u2014a retrospective study in three Swiss Travel Clinics","volume":"25","author":"Huber","year":"2018","journal-title":"J. Travel Med."},{"issue":"43","key":"10.1016\/j.biopha.2023.115254_bib79","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib80","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tmaid.2014.01.005","article-title":"Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study","volume":"12","author":"Askling","year":"2014","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.115254_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tmaid.2017.12.004","article-title":"An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression - a prospective, open-label, multi-center study","volume":"21","author":"Rosdahl","year":"2018","journal-title":"Travel Med. Infect. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2023.115254_bib82","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.biopha.2023.115254_bib83","first-page":"13","article-title":"Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19\/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115254_bib84","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","article-title":"Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002293","article-title":"Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination","volume":"8","author":"Andreica","year":"2022","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib86","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/annrheumdis-2021-220862","article-title":"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis","volume":"80","author":"Bugatti","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2023.115254_bib87","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2023.115254_bib88","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib89","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00296-022-05123-2","article-title":"Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis","volume":"42","author":"Feuchtenberger","year":"2022","journal-title":"Rheumatol. Int."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib90","article-title":"Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases","volume":"81","author":"De Silva","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2023.115254_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.811829","article-title":"Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: can therapy affect the immunological response?","volume":"9","author":"Benucci","year":"2022","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001898","article-title":"Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases","volume":"8","author":"Sieiro Santos","year":"2022","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib93","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1136\/rmdopen-2022-002650","article-title":"Original research: type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease","volume":"8","author":"Frommert","year":"2022","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib94","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/annrheumdis-2021-221097","article-title":"BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus","volume":"81","author":"Moyon","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22839-0","article-title":"Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases","volume":"12","author":"Zheng","year":"2022","journal-title":"Sci. Rep."},{"issue":"42","key":"10.1016\/j.biopha.2023.115254_bib96","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031288","article-title":"Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study","volume":"101","author":"Sugihara","year":"2022","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105464","article-title":"The impact of immunomodulating treatment on the immunogenicity of COVID-19 vacci Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis","volume":"90","author":"G.S. Saad","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.biopha.2023.115254_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.03.065","article-title":"The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)","author":"Frodlund","year":"2023","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.biopha.2023.115254_bib99","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib100","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001914","article-title":"Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies","volume":"7","author":"Tani","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.biopha.2023.115254_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102743","article-title":"A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases","volume":"125","author":"Tzioufas","year":"2021","journal-title":"J. Autoimmun."},{"issue":"SI2","key":"10.1016\/j.biopha.2023.115254_bib103","doi-asserted-by":"crossref","first-page":"SI180","DOI":"10.1093\/rheumatology\/keac089","article-title":"Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions","volume":"61","author":"Krasselt","year":"2022","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib104","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1007\/s10067-022-06348-z","article-title":"Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients","volume":"41","author":"Pri-Paz Basson","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.biopha.2023.115254_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1033804","article-title":"Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients","volume":"13","author":"Wro\u0144ski","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115254_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.960001","article-title":"Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis","volume":"13","author":"Nemeth","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib107","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12916-022-02587-8","article-title":"The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study","volume":"20","author":"Christensen","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33042-0","article-title":"Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients","volume":"13","author":"Silva","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib109","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002632","article-title":"Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis","volume":"8","author":"Stahl","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.biopha.2023.115254_bib110","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/hptln9","article-title":"Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors","author":"Venerito","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-222096","article-title":"Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases","volume":"81","author":"Aikawa","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib112","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3390\/v15030620","article-title":"The kinetics of humoral and cellular responses after the booster dose of COVID-19 vaccine in inflammatory arthritis patients","volume":"15","author":"Wro\u0144ski","year":"2023","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.biopha.2023.115254_bib113","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2023.115254_bib114","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77969","article-title":"Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273","volume":"11","author":"Verstegen","year":"2022","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.biopha.2023.115254_bib115","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","article-title":"Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"76","author":"Park","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib116","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2023.115254_bib117","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/annrheumdis-2019-215187","article-title":"Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial","volume":"78","author":"Park","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib118","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10067-019-04857-y","article-title":"Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials","volume":"39","author":"Park","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-221916","article-title":"Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial","volume":"81","author":"Araujo","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2023.115254_bib120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-2600(22)00186-2","article-title":"Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial","volume":"10","author":"Abhishek","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib121","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002203","article-title":"Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?","volume":"8","author":"Laster","year":"2022","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib122","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/rheumatology\/keh088","article-title":"Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review","volume":"43","author":"Whittle","year":"2003","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib123","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"Van Ede","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib124","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10067-018-4011-8","article-title":"Methotrexate preferentially affects Tc1 and Tc17 subset of CD8 T lymphocytes","volume":"38","author":"Sandhu","year":"2019","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib125","doi-asserted-by":"crossref","DOI":"10.1007\/BF00207484","article-title":"Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis","volume":"72","author":"Wascher","year":"1994","journal-title":"Clin. Investig."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib126","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00011-005-1355-8","article-title":"Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines","volume":"54","author":"Herman","year":"2005","journal-title":"Inflamm. Res."},{"issue":"9","key":"10.1016\/j.biopha.2023.115254_bib127","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/art.30457","article-title":"Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK","volume":"63","author":"Spurlock","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.biopha.2023.115254_bib128","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.34342","article-title":"Methotrexate increases expression of cell cycle checkpoint genes via JNK activation","volume":"64","author":"Spurlock","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2023.115254_bib130","first-page":"14","article-title":"Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge","author":"Gary","year":"2023","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115254_bib131","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1002\/art.38805","article-title":"Methotrexate inhibits NF-\u03baB activity via long intergenic (noncoding) RNA-p21 induction","volume":"66","author":"Spurlock","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib132","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/rheumatology\/keu279","article-title":"Methotrexate-mediated inhibition of nuclear factor \u03baB activation by distinct pathways in T cells and fibroblast-like synoviocytes","volume":"54","author":"Spurlock","year":"2015","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130078","article-title":"Methotrexate Is a JAK\/STAT Pathway Inhibitor","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000287","article-title":"Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures","volume":"2","author":"Kremer","year":"2016","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.biopha.2023.115254_bib135","first-page":"1189","article-title":"Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis","volume":"42","author":"Gerards","year":"2003","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib136","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.59.4.311","article-title":"Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4","volume":"59","author":"Rudwaleit","year":"2000","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib137","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri1052","article-title":"Cytokine control of memory T-cell development and survival","volume":"3","author":"Schluns","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib138","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.it.2005.01.004","article-title":"IL-7: maintaining T-cell memory and achieving homeostasis","volume":"26","author":"Bradley","year":"2005","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib139","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/ard.2007.081059","article-title":"Reduction of serum interleukin 7 levels upon methotrexate therapy in early rheumatoid arthritis correlates with disease suppression","volume":"67","author":"van Roon","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1365-2249.1999.00753.x","article-title":"Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression","volume":"115","author":"Neurath","year":"2001","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib141","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib142","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/03009740701406460","article-title":"Soluble cell adhesion molecules (sICAM\u20101, sVCAM\u20101, and sE\u2010selectin) in patients with early rheumatoid arthritis","volume":"36","author":"Klimiuk","year":"2007","journal-title":"Scand. J. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib143","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/imr.12741","article-title":"Extrafollicular responses in humans and SLE","volume":"288","author":"Jenks","year":"2019","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib144","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.immuni.2009.01.011","article-title":"Initial clonal expansion of germinal center B cells takes place at the perimeter of follicles","volume":"30","author":"Coffey","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2023.115254_bib145","first-page":"10","article-title":"The maintenance of memory plasma cells","author":"Khodadadi","year":"2019","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2023.115254_bib146","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/art.38736","article-title":"Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis","volume":"66","author":"Glaesener","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115254_bib147","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0753-3322(03)00086-6","article-title":"Decrease of B-cells and autoantibodies after low-dose methotrexate","volume":"57","author":"B\u00f6hm","year":"2003","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.biopha.2023.115254_bib148","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","article-title":"Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases","volume":"32","author":"Mok","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115254_bib149","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2023.115254_bib150","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213403","article-title":"Methotrexate and BAFF interaction prevents immunization against TNF inhibitors","volume":"77","author":"Bitoun","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2023.115254_bib151","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/annrheumdis-2018-214025","article-title":"Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis","volume":"78","author":"Park","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2023.115254_bib152","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.4049\/jimmunol.1303326","article-title":"Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa","volume":"193","author":"Joly","year":"2014","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115254_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081860","article-title":"Tuning monocytes and macrophages for personalized therapy and diagnostic challenge in rheumatoid arthritis","volume":"10","author":"Roszkowski","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2023.115254_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102964","article-title":"Monocyte activation in systemic Covid-19 infection: assay and rationale","volume":"59","author":"Martinez","year":"2020","journal-title":"EBioMedicine"},{"issue":"7914","key":"10.1016\/j.biopha.2023.115254_bib155","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-022-04702-4","article-title":"Fc\u03b3R-mediated SARS-CoV-2 infection of monocytes activates inflammation","volume":"606","author":"Junqueira","year":"2022","journal-title":"Nature"},{"issue":"7872","key":"10.1016\/j.biopha.2023.115254_bib156","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature2"},{"issue":"4","key":"10.1016\/j.biopha.2023.115254_bib157","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41590-022-01168-4","article-title":"Making innate sense of mRNA vaccine adjuvanticity","volume":"23","author":"Kobiyama","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-021-00329-3","article-title":"Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines","volume":"7","author":"Liu","year":"2021","journal-title":"Cell Discov."},{"issue":"12","key":"10.1016\/j.biopha.2023.115254_bib159","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2015-208736","article-title":"Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase\/p53 axis","volume":"75","author":"Municio","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2023.115254_bib160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282564","article-title":"Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab","volume":"18","author":"Talmon","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib161","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000287","article-title":"Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures","volume":"2","author":"Kremer","year":"2016","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.biopha.2023.115254_bib162","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/annrheumdis-2017-212537","article-title":"Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism","volume":"77","author":"Municio","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2023.115254_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.776879","article-title":"The macrophage reprogramming ability of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis","volume":"12","author":"Fuentelsaz-Romero","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115254_bib164","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7561661","article-title":"Methotrexate treatment suppresses monocytes in nonresponders to pneumococcal conjugate vaccine in rheumatoid arthritis patients","volume":"2022","author":"Elm\u00e9r","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.biopha.2023.115254_bib165","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.2147\/IJN.S371183","article-title":"Microneedle patch delivery of methotrexate-loaded albumin nanoparticles to immune cells achieves a potent antipsoriatic effect","volume":"17","author":"Wang","year":"2022","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.biopha.2023.115254_bib166","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/ar3248","article-title":"Tumor necrosis factor-alpha promotes survival in methotrexate-exposed macrophages by an NF-kappaB-dependent pathway","volume":"13","author":"Lo","year":"2011","journal-title":"Arthritis Res. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:57:21Z","timestamp":1777877841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223010454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":166,"alternative-id":["S0753332223010454"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115254","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients \u2013 Lessons learned from the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115254"}}